Nestlé S.A.: Investing in breakthrough 'Ecobiotics' to tackle serious public health issues Montag, 11. Januar 2016 - 13:30
 |
Nestlé Health Science has signed an exclusive agreement outside of the United States and Canada to support the potential future commercialisation of Seres Therapeutics' novel 'microbiome therapeutics'.
Greg Behar, CEO of Nestlé Skin Health, will be available for interview from 15:00 CET today.
If you are a journalist, please call, +41 44 511 1661 (Europe, Switzerland), +1 855 315 9070 or +1 212 497 6321 (United States). Then enter the conference ID: 31990573#
Read more: www.nestle.com/media/news/Nestle-Health-Science-investment-Seres-Ecobiotics
More stories on our Nestlé News Feed: www.nestle.com/media
Media enquiries
Nestlé S.A. Vevey, Switzerland
Tel: +41 21 924 2200
Email: mediarelations@nestle.com
Follow Nestlé news
Twitter | Flickr | Facebook | YouTube